These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 10919660)
21. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. Furger C; Fiddes RJ; Quinn DI; Bova RJ; Daly RJ; Sutherland RL Cancer Res; 1998 May; 58(9):1773-8. PubMed ID: 9581810 [TBL] [Abstract][Full Text] [Related]
22. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676 [TBL] [Abstract][Full Text] [Related]
23. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Motoyama AB; Hynes NE; Lane HA Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928 [TBL] [Abstract][Full Text] [Related]
24. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice. van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875 [TBL] [Abstract][Full Text] [Related]
25. Perturbation of beta1-integrin function alters the development of murine mammary gland. Faraldo MM; Deugnier MA; Lukashev M; Thiery JP; Glukhova MA EMBO J; 1998 Apr; 17(8):2139-47. PubMed ID: 9545227 [TBL] [Abstract][Full Text] [Related]
26. Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Wechselberger C; Strizzi L; Kenney N; Hirota M; Sun Y; Ebert A; Orozco O; Bianco C; Khan NI; Wallace-Jones B; Normanno N; Adkins H; Sanicola M; Salomon DS Oncogene; 2005 Jun; 24(25):4094-105. PubMed ID: 15897912 [TBL] [Abstract][Full Text] [Related]
27. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. Tomblyn S; Langenheim JF; Jacquemart IC; Holle E; Chen WY Int J Oncol; 2005 Nov; 27(5):1381-9. PubMed ID: 16211235 [TBL] [Abstract][Full Text] [Related]
29. Characterization of a novel primary mammary tumor cell line reveals that cyclin D1 is regulated by the type I insulin-like growth factor receptor. Jones RA; Campbell CI; Petrik JJ; Moorehead RA Mol Cancer Res; 2008 May; 6(5):819-28. PubMed ID: 18505926 [TBL] [Abstract][Full Text] [Related]
30. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Menendez JA; Mehmi I; Lupu R Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820 [TBL] [Abstract][Full Text] [Related]
31. ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. Loureiro RM; Maharaj AS; Dankort D; Muller WJ; D'Amore PA Biochem Biophys Res Commun; 2005 Jan; 326(2):455-65. PubMed ID: 15582599 [TBL] [Abstract][Full Text] [Related]
32. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Ren J; Bharti A; Raina D; Chen W; Ahmad R; Kufe D Oncogene; 2006 Jan; 25(1):20-31. PubMed ID: 16158055 [TBL] [Abstract][Full Text] [Related]
33. Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus. Miralem T; Avraham HK Mol Cell Biol; 2003 Jan; 23(2):579-93. PubMed ID: 12509456 [TBL] [Abstract][Full Text] [Related]
34. beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Michaelson JS; Leder P Oncogene; 2001 Aug; 20(37):5093-9. PubMed ID: 11526497 [TBL] [Abstract][Full Text] [Related]
35. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601 [TBL] [Abstract][Full Text] [Related]
36. The oncogene heregulin induces apoptosis in breast epithelial cells and tumors. Weinstein EJ; Grimm S; Leder P Oncogene; 1998 Oct; 17(16):2107-13. PubMed ID: 9798682 [TBL] [Abstract][Full Text] [Related]
37. Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. Jones FE; Jerry DJ; Guarino BC; Andrews GC; Stern DF Cell Growth Differ; 1996 Aug; 7(8):1031-8. PubMed ID: 8853899 [TBL] [Abstract][Full Text] [Related]
38. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression. Hardy S; Wong NN; Muller WJ; Park M; Tremblay ML Cancer Res; 2010 Nov; 70(21):8959-67. PubMed ID: 20841483 [TBL] [Abstract][Full Text] [Related]
39. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Hu C; Diévart A; Lupien M; Calvo E; Tremblay G; Jolicoeur P Am J Pathol; 2006 Mar; 168(3):973-90. PubMed ID: 16507912 [TBL] [Abstract][Full Text] [Related]
40. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]